Cardio Pulmonary Disorders
Cardiopulmonary disease encompasses critical conditions affecting the heart and lungs, with Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disorder (COPD) being primary tobacco-associated illnesses. Tobacco smoke exposure significantly elevates the risk of CVD, while minimizing exposure is key in preventing COPD. However, the precise mechanisms by which tobacco toxicants contribute to CVD and COPD onset remain unclear. Despite smoking reductions, CVD and COPD persist as leading causes of death among smokers. Notably, each smoking-related death equates to at least 30 individuals living with serious smoking-related ailments.
The rise of e-cigarettes and similar tobacco products, delivering aerosolized nicotine and chemical flavorings, poses new concerns for cardiopulmonary health, especially among adolescents. Their increasing popularity suggests they may surpass traditional cigarettes in the market. These products warrant thorough investigation into their potential risks for cardiopulmonary diseases.
- Experience with CPX in Selected Patient Populations
- Congenital Heart Defects, Valve Disease, and Hypertrophic Cardiomyopathy
- Left Ventricular Dysfunction Secondary to Myocardial Ischemia
- Application of CPX in the Clinical Care of Patients with Cardiopulmonary Diseases
- Prognostic Assessment of Candidates for Transplantation or Other Major Interventions
Related Conference of Cardio Pulmonary Disorders
5th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
17th International Conference on Chronic Obstructive Pulmonary Disease
Cardio Pulmonary Disorders Conference Speakers
Recommended Sessions
- Advancements in Pulmonary Diagnostics
- Cardio Pulmonary Disorders
- Chronic Obstructive Pulmonary Disease
- COVID-19 and Asthma
- COVID-19 and Respiratory System
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Lung Cancer
- Lung Transplantation
- Obstructive Sleep Apnea
- Occupational Lung Diseases
- Pneumonia
- Pulmonary diseases: Treatment, Diagnosis and therapies
- Pulmonary Hypertension
- Pulmonary Rehabilitation
- Tuberculosis
Related Journals
Are you interested in
- Advances in Tuberculosis Diagnosis, Treatment, and Prevention - Tuberculosis-2025 (France)
- Asthma - Pulmonary Meet 2025 (France)
- Asthma and COPD - COPD_2025 (Spain)
- Chronic Bronchitis - Pulmonary Meet 2025 (France)
- Chronic Obstructive Pulmonary Disease - COPD_2025 (Spain)
- Co-Morbidities of COPD - COPD_2025 (Spain)
- Community-based Approaches to TB and Lung Health Awareness - Tuberculosis-2025 (France)
- COPD - Pulmonary Meet 2025 (France)
- COPD and Cardiovascular Diseases - COPD_2025 (Spain)
- COPD Complications - COPD_2025 (Spain)
- COPD Exacerbations - COPD_2025 (Spain)
- COPD Pathogenesis - COPD_2025 (Spain)
- COPD Therapeutics - COPD_2025 (Spain)
- COPD: Sign and Symptoms - COPD_2025 (Spain)
- Cystic Fibrosis - Pulmonary Meet 2025 (France)
- Depression and anxiety in COPD - COPD_2025 (Spain)
- Digital Health Technologies for Respiratory Disease Management - Tuberculosis-2025 (France)
- Drug Discovery of COPD - COPD_2025 (Spain)
- Early Diagnosis and Biomarkers in Respiratory Diseases - Tuberculosis-2025 (France)
- Emerging Respiratory Threats and Pandemic Preparedness - Tuberculosis-2025 (France)
- Emphysema - Pulmonary Meet 2025 (France)
- Epidemiology of COPD - COPD_2025 (Spain)
- Genetic risk factor of COPD - COPD_2025 (Spain)
- Genetics and Susceptibility to Tuberculosis and Lung Diseases - Tuberculosis-2025 (France)
- Global Efforts to Eliminate Tuberculosis by 2030 - Tuberculosis-2025 (France)
- Hospital-acquired Infections and Respiratory Care - Tuberculosis-2025 (France)
- Impact of Smoking and Environmental Factors on Lung Health - Tuberculosis-2025 (France)
- Infectious Respiratory Diseases - Pulmonary Meet 2025 (France)
- Interstitial lung disease - Pulmonary Meet 2025 (France)
- Latent Tuberculosis: Diagnosis, Treatment, and Control - Tuberculosis-2025 (France)
- Lung cancer - COPD_2025 (Spain)
- Lung Cancer - Pulmonary Meet 2025 (France)
- Lung Health: Emerging Trends and Challenges - Tuberculosis-2025 (France)
- Lung problems - Pulmonary Meet 2025 (France)
- Lung transplantation - Pulmonary Meet 2025 (France)
- Multidrug-Resistant Tuberculosis (MDR-TB) and Novel Therapies - Tuberculosis-2025 (France)
- Neonatal and Maternal Respiratory Health - Tuberculosis-2025 (France)
- Novel Therapies and Drug Development for Tuberculosis - Tuberculosis-2025 (France)
- Pathophysiology of COPD - COPD_2025 (Spain)
- Pediatric Pulmonary, Critical care and Sleep - COPD_2025 (Spain)
- Pediatric Tuberculosis and Respiratory Health - Tuberculosis-2025 (France)
- Pleural Diseases - Pulmonary Meet 2025 (France)
- Prevention and Control of Respiratory disease - Pulmonary Meet 2025 (France)
- Pulmonary diseases-treatment and therapies - COPD_2025 (Spain)
- Pulmonary Hypertension - Pulmonary Meet 2025 (France)
- Pulmonary Hypertension - COPD_2025 (Spain)
- Pulmonary Rehabilitation - Pulmonary Meet 2025 (France)
- Pulmonary Rehabilitation and Holistic Care for Respiratory Diseases - Tuberculosis-2025 (France)
- Pulmonary vascular disease - Pulmonary Meet 2025 (France)
- Pulmonology - Pulmonary Meet 2025 (France)
- Respiratory Disorders - Pulmonary Meet 2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Tract Infections - Pulmonary Meet 2025 (France)
- Role of Artificial Intelligence in Tuberculosis Diagnosis - Tuberculosis-2025 (France)
- Self-Management and Prevention of COPD - COPD_2025 (Spain)
- Sleep-Related Respiratory Disorders - Pulmonary Meet 2025 (France)
- Tuberculosis - Pulmonary Meet 2025 (France)
- Tuberculosis and HIV Co-infection: Challenges and Treatment - Tuberculosis-2025 (France)
- Tuberculosis Prevention and Global Public Health Strategies - Tuberculosis-2025 (France)
- Types of COPD - COPD_2025 (Spain)